Integrin α2β1 Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer-Reference-Cited by-同舟云学术

Integrin α2β1 Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer

Published:2021-06-17 Issue:7 Volume:18 Page:2634-2646
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Zhou Bingjie¹,Li Min¹,Xu Xiaomin¹,Yang Lan¹,Ye Meiling¹,Chen Yan¹,Peng Jiayi¹,Xiao Linyu¹,Wang Luyao¹,Huang Shiqi¹,Zhang Ling²^ORCID,Lin Qing¹^ORCID,Zhang Zhirong¹^ORCID

Affiliation:

1. Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, P.R. China

2. College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, P.R. China

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Sichuan University postdoctoral interdisciplinary Innovation Fund

the Fundamental Research Funds for the Central Universalities of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.1c00132